Learning Objectives:
Describe the genotypic and phenotypic spectrum of ADPKD
Improve recognition of potentially undiagnosed Alport Syndrome in patients with hematuria and proteinuric kidney disease
Understand differences in prevalence and severity of genetic kidney diseases in the general population vs. disease-focused cohorts
As a physician-scientist, practicing nephrologist, and acting co-Director of the Kidney Health Research Institute at Geisinger Health, Dr. Chang has devoted his clinical and scientific career to preventing and decreasing the burden of chronic kidney disease (CKD) and its complications. His research program includes: epidemiologic research using electronic health record (EHR) data from Geisinger and other large cohorts to study risk factors and the burden of CKD and CKD pharmacoepidemiology; leading interventional clinical trials with the aim of improving early identification of CKD and reducing risks of cardiovascular and kidney disease. Over the last few years, Dr. Chang has extended his work examining risk factors of CKD to genetics-examining the phenotypic spectrum of rare variants in genes associated with kidney disease. Dr. Chang has served on national committees and scientific workshops for the National Kidney Foundation, the American Society of Nephrology, and the American Heart Association, and currently serves on the editorial board for CJASN. His clinical duties include leading system-wide efforts to improve hypertension care at Geisinger and overseeing population health dashboards for CKD and hypertension, allowing for the rapid translation of research findings directly into clinical care. In summary, Dr. Chang has a record of highly productive clinical research in CKD and hypertension as well as leadership and national recognition and was recently awarded the Mark Bieber Award by the American Heart Association at the AHA Epidemiology/Lifestyle 2022 Scientific Sessions. His research efforts have influenced national and international clinical guidelines, gene-disease validity classification by ClinGen, and National Committee for Quality Assurance recommended measures for health plans.
Негізгі бет Rare Genetic Variants to Kidney Disease with Dr Alex Chang
Пікірлер